EIS: Israel Caught Up In The Tech Selloff, Where To Be A Buyer
https://seekingalpha.com/article/4772074-eis-etf-attractive-valuation-cautionary-technical-indicators?source=feed_tag_etf_portfolio_strategy
Mar 31, 2025 -
0
NLS Pharmaceutics announces up to $3M and $25M equity facility agreement to support merger with Kadimastem
https://seekingalpha.com/news/4426938-nls-pharmaceutics-announces-up-to-3m-and-25m-equity-facility-agreement-to-support-merger-with-kadimastem?source=feed_sector_healthcare
Mar 31, 2025 -
0
Stop Plunging Toilets For Your Tenants - Get Paid Up To 7.5% Yields Instead
https://seekingalpha.com/article/4771704-stop-plunging-toilets-for-your-tenants-get-paid-7-5-percent-yields-instead?source=feed
Mar 31, 2025 -
0
IDEAYA Gets FDA Breakthrough Therapy Designation For Darovasertib In Neoadjuvant UM; Stock Up
https://www.rttnews.com/story.aspx?Id=3525443
Mar 31, 2025 - IDEAYA Biosciences, Inc. (IDYA), a precision medicine oncology company, announced Monday that the U.S. Food and Drug Administration has granted Breakthrough Therapy designation or BTD for darovasertib monotherapy in neoadjuvant uveal melanoma.
0
CoreWeave: Rent Is Going Up, Get Out Now
https://seekingalpha.com/article/4771259-coreweave-rent-is-going-up-get-out-now?source=feed_tag_ipo_analysis
Mar 28, 2025 -
0
Dermata Therapeutics Says Phase 3 STAR-1 Study Of Xyngari To Treat Acne Met Primary Goals; Stock Up
https://www.rttnews.com/story.aspx?Id=3524842
Mar 27, 2025 - Dermata Therapeutics, Inc. (DRMA) Thursday reported positive topline results from the pivotal Phase 3 STAR-1 study of the company's lead product candidate Xyngari for the treatment of acne. The study met its primary goals. The company's shares were more than 50 percent up in pre-market.
0
Winnebago Q2 Results Beat Market, Cuts FY25 Outlook; Stock Up In Pre-market
https://www.rttnews.com/story.aspx?Id=3524779
Mar 27, 2025 - Winnebago Industries Inc. (WGO) on Thursday trimmed fiscal 2025 earnings and revenues outlook after reporting narrower net loss and weak revenues in its second quarter. However, quarterly results beat market estimates.
0
Uxin: Why Its Future Is Still Up In The Air
https://seekingalpha.com/article/4770731-uxin-why-its-future-is-still-up-in-the-air?source=feed_all_articles
Mar 26, 2025 -
0
FLGR: Macros Are On The Up, But Wait For A Retracement
https://seekingalpha.com/article/4770593-flgr-macros-are-on-the-up-but-wait-for-a-retracement?source=feed_tag_etf_portfolio_strategy
Mar 26, 2025 -
0
23andMe’s DNA database is up for sale. Who might want it, and what for?
https://www.boston.com/news/business/2025/03/26/23andmes-dna-database-is-up-for-sale-who-might-want-it-and-what-for/
Mar 26, 2025 -
If someone shared their DNA with 23andMe, experts say they should delete their data immediately and request the company to dispose of any genetic material samples.
The post 23andMe’s DNA database is up for sale. Who might want it, and what for? appeared first on Boston.com.
0